CELC Earnings Prediction
The chart below shows how CELC performed 10 days before and after its earnings report, based on data from the past quarters. Typically, CELC sees a +0.15% change in stock price 10 days leading up to the earnings, and a +2.17% change 10 days following the report. On the earnings day itself, the stock moves by +0.33%. This data can give you a slight idea of what to expect for the next quarter's release.
CELC Key Earning Data
CELC Earnings Analysis
Positive
Clinical Development Advancements: Significant progress in clinical development programs, including completion of enrollment for VIKTORIA-1 and selection of sites for VIKTORIA-2.
Upcoming Clinical Data Readouts: Anticipation of important clinical data readouts in 2025, including top line data for VIKTORIA-1 in Q2 and Q4.
Blockbuster Revenue Potential: Gedatolisib shows potential for blockbuster revenue with an estimated 200,000 late-stage cancer patients eligible for treatment.
Tolerability and Discontinuation Rate: Gedatolisib demonstrated favorable tolerability with a low treatment-related discontinuation rate of 4%, which is competitive compared to other therapies.
Overall Survival Data Highlights: Positive preliminary overall survival data from Phase Ib study, with median overall survival of 77 months for first-line patients and 34 months for second-line patients.
Site Selection Completion: Completion of site selection for VIKTORIA-2 study, with approximately 200 sites activated globally, indicating strong interest in the trial.
Market Expansion Opportunity: Potential market expansion with VIKTORIA-2 targeting an additional $3 billion market for endocrine therapy-resistant advanced breast cancer.
Cash Position Improvement: Strong financial position with $235.1 million in cash and equivalents at year-end, up from $180.6 million in 2023.
Negative
Earnings Miss Reported: Celcuity Inc. misses on earnings expectations with reported EPS of $-0.85, below the expected $-0.72.
Net Loss Increase: Net loss for Q4 2024 was $36.7 million, an increase from $18.8 million in Q4 2023, indicating worsening financial performance.
Net Loss Increase: Full year net loss for 2024 was $111.8 million, compared to $63.8 million in 2023, showing a significant increase in losses year-over-year.
Adjusted Net Loss Increase: Non-GAAP adjusted net loss for Q4 2024 was $32.3 million, up from $17.6 million in Q4 2023, reflecting increased operational costs.
Rising R&D Expenses: Research and development expenses surged to $33.5 million in Q4 2024, compared to $18.1 million in Q4 2023, indicating rising costs without immediate revenue generation.
Rising Administrative Expenses: General and administrative expenses also increased to $3 million in Q4 2024 from $1.6 million in Q4 2023, highlighting growing operational overhead.
Operating Cash Burn Increase: Net cash used in operating activities for Q4 2024 was $27.8 million, up from $18.5 million in Q4 2023, indicating higher cash burn.
Operating Cash Flow Decline: Net cash used in operating activities for the full year 2024 was $83.5 million, compared to $53.8 million in 2023, reflecting a concerning trend in cash flow management.
CELC FAQs
How does CELC typically perform around its earnings report dates?
CELC's stock performance around earnings reports can vary, but historical data shows specific patterns, such as a +0.15% change leading up to the report and a +2.17% change in the 10 days following the release.
Is Celcuity Inc (CELC) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
CELC Earning Call Sentiment
Celcuity Inc. (NASDAQ:CELC) Q4 2024 Earnings Call Transcript
CELC.O
0.93%
